ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
07 Aug 2022 15:29

Hong Kong Connect Flows: Tencent, Ganfeng Lithium, Meituan, Kuaishou, Wuxi Biologics

Southbound Hong Kong connected recorded inflows of $826m last week. We highlight inflows for Tencent, Ganfeng Lithium, and outflows from Meituan,...

Logo
208 Views
Share
07 Aug 2022 15:28

HK Short Interest: Kuaishou, Alibaba, Cifi, Netease

We highlight week on week short interest changes in Kuaishou, Alibaba, Cifi, and Netease based on the latest HK SFC Short Aggregate report.

Logo
195 Views
Share
31 Jul 2022 11:31

Hong Kong Connect Flows: Tencent, Wuxi Biologics, China Mobile

Inflows from mainland investors to Hong Kong stocks have been positive for the past 12 weeks. We highlight flows for Tencent, Wuxi Biologics, and...

Logo
294 Views
Share
31 Jul 2022 11:04

HK Short Interest: Wuxi Biologics, Techtronic, Tencent, XPeng

We highlight weekly short interests changes in Wuxi Biologics, Techtronic, Tencent, XPeng based on the latest HK SFC Short Aggregate report.

Logo
273 Views
Share
26 Jul 2022 11:44

Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction

Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...

Logo
300 Views
Share
x